Stockscreener 앱 받기
101.68
4.73%
4.59
시간 외 거래:
101.68
전일 마감가:
$97.09
열려 있는:
$98.45
하루 거래량:
1.92M
Relative Volume:
2.42
시가총액:
$6.49B
수익:
$46.02M
순이익/손실:
$-130.15M
주가수익비율:
-49.78
EPS:
-2.0427
순현금흐름:
$56.08M
1주 성능:
+6.56%
1개월 성능:
+22.37%
6개월 성능:
+63.47%
1년 성능:
+87.08%
1일 변동 폭
$98.34
$105.69
1주일 범위
$90.58
$105.69
52주 변동 폭
$39.60
$105.69
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
101.68 | 6.20B | 46.02M | -130.15M | 56.08M | -2.0427 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
PTGX Analyst Rating Update: Leerink Partners Raises Price Target to $110 | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Protagonist Therapeutics (PTGX) Receives Rating Update from JP M - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade - MarketBeat
Citigroup Raises Price Target for PTGX to $125, Maintains Buy Ra - GuruFocus
Johnson & Johnson-Protagonist Therapeutics partnered new psoriasis pill wins FDA nod, shakes up competition with AbbVie - MSN
Protagonist Therapeutics (PTGX) Sees Target Price Upgrade from B - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $119.00 Price Target at Barclays - MarketBeat
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Clear Street raises Protagonist Therapeutics price target on FDA approval By Investing.com - Investing.com Canada
Icotyde’s in; wave of switchers to oral psoriasis Protagonist? - BioWorld MedTech
How an East Bay company picked up $50 million with another $580 million potentially on the way - The Business Journals
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026 - Meyka
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
CEO Moves: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Barclays raises Protagonist Therapeutics stock price target on FDA approval - Investing.com
Jefferies raises Protagonist Therapeutics price target on drug approval By Investing.com - Investing.com Canada
Jefferies raises Protagonist Therapeutics price target on drug approval - Investing.com
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis TreatmentSlideshow (NASDAQ:PTGX) 2026-03-18 - Seeking Alpha
Protagonist Therapeutics stock gets Truist buy rating reiterated By Investing.com - Investing.com Canada
FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment - Traders Union
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist - Seeking Alpha
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis - ACCESS Newswire
FDA approves first oral IL-23 psoriasis pill, Protagonist lands $50M - Stock Titan
Protagonist Therapeutics stock hits all-time high at 98.65 USD By Investing.com - Investing.com South Africa
Protagonist Therapeutics stock hits all-time high at 98.65 USD - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighHere's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC - MarketBeat
Farallon Capital Management LLC Acquires 24,000 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC - MarketBeat
Commodore Capital LP Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD By Investing.com - Investing.com Nigeria
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC - MarketBeat
PTGX: Lead peptide assets near approval as diversified pipeline and partnerships drive future growth - TradingView
Atika Capital Management LLC Takes $5.51 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bergen Record
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
Wall Street Recap: Is Protagonist Therapeutics Inc trading at a discount2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
PTGX: Two late-stage oral peptide drugs near approval, with strong pipeline and financial flexibility - TradingView
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Enterprise News
Responsive Playbooks and the PTGX Inflection - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighShould You Buy? - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD - Investing.com India
Nasdaq Moves: Can Protagonist Therapeutics Inc expand into new markets2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)? - Sahm
Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):